Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Global Sales and Marketing Meeting - GSM 2023

Hi there! Find here the relevant information about the Global Sales, Marketing & Communications and PMO Meeting in Lisbon, Portugal.

Page
Read more

Certificate of Suitability (CEP)

EP Certificates - Granted by EDQM

Page
Read more

Procurement

We partner, connect and align to shape supplier solutions that help Hovione reach its growth and objectives.

Page
Read more